Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Accured Expenses for 10 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 91.73% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.9 million, a 0.12% change, with the full-year FY2025 number at $21.9 million, changed 0.12% from a year prior.
  • Change in Accured Expenses was $1.3 million for Q4 2025 at Rhythm Pharmaceuticals, down from $11.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $15.7 million in Q4 2022 to a low of -$12.6 million in Q3 2022.
  • A 5-year average of $3.9 million and a median of $4.5 million in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 309.83% in 2022, then soared 9849.06% in 2023.
  • Rhythm Pharmaceuticals' Change in Accured Expenses stood at $12.9 million in 2021, then rose by 21.61% to $15.7 million in 2022, then tumbled by 69.08% to $4.9 million in 2023, then soared by 212.45% to $15.2 million in 2024, then plummeted by 91.73% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Change in Accured Expenses are $1.3 million (Q4 2025), $11.0 million (Q3 2025), and $13.3 million (Q2 2025).